661 results on '"van den Heuvel, Michel"'
Search Results
102. Erratum to: Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer
103. Late Breaking Abstract - Recovering after COVID-19: 10-month follow-up data from a multidisciplinary outpatient clinic
104. Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
105. Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment
106. An Uncommon Presentation of Brain Metastases in a Lung Cancer Patient
107. Comments on Predictors of Clinical Use of Pleurodesis and/or Indwelling Pleural Catheter Therapy for Malignant Pleural Effusion
108. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
109. Immunotherapy in Non–Small-Cell Lung Carcinoma: From Inflammation to Vaccination
110. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy
111. Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion
112. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
113. Hyperhydration with cisplatin does not influence pemetrexed exposure
114. Recent Advances and Future Perspective of DC-Based Therapy in NSCLC
115. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer
116. Additional file 2 of Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
117. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment
118. Clinical utility of plasma-based comprehensive molecular profiling in advanced non-small-cell lung cancer
119. Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment
120. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19
121. Non-invasive diagnosis of pleural malignancies: The role of tumour markers
122. Costs, throughput time, and proportion of valid test results, a model-based analysis of liquid biopsies for stage IV non-small cell lung cancer.
123. An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection
124. Where the nose is going to help the eye: Sniffing lung cancer
125. Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
126. Lung Cancer in the Netherlands
127. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
128. The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer:A systematic review
129. Comparability of PD-L1 immunohistochemistry assays for non-small cell lung cancer: a systematic review
130. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19
131. Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
132. Barriers and Facilitators for Implementation of a Computerized Clinical Decision Support System in Lung Cancer Multidisciplinary Team Meetings—A Qualitative Assessment
133. The Use of Indwelling Pleural Catheters for the Management of Malignant Pleural Effusion - Direct Costs in a Dutch Hospital
134. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing
135. The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer.
136. Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19)
137. Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
138. Treatable traits qualifying for nonpharmacological interventions in COPD patients upon first referral to a pulmonologist: the COPD sTRAITosphere
139. Late Breaking Abstract - External validation of exhaled-breath analysis to detect non-small cell lung cancer: a step-wise design to simultaneously develop and validate a prediction model
140. Clinical efficacy of the COPDnet integrated care model
141. Late Breaking Abstract - Plasma cells and endothelitis in COVID-19 lung pathology
142. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test
143. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease
144. Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
145. A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection
146. The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of non-small cell lung cancer: A systematic review.
147. Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC
148. Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
149. Programmed Cell Death-1/Ligand-1 PET Imaging
150. Plasma Cells and Endothelitis in COVID-19 Lung Pathology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.